Jul 30, 2026
Beyond Digitalization: Why Cognitization Will Define the Next Era of Supply Chains
Read More
Cancer Immunotherapies Represent a Multi-billion Dollar Opportunity
Recently, the US Food and Drug Administration (USFDA) approved Dendreon Corp.’s Provenge, for prostate cancer, and Bristol-Myers Squibb Co.’s Yervoy, for melanoma. As one of the early-movers into the cancer immunotherapy space, Dendreon was successful in significantly reducing entry barriers for firms engaged in immunotherapy
